These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9496909)

  • 21. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
    Rowinsky EK; Windle JJ; Von Hoff DD
    J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
    Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
    Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
    Girgert R; Hohnecker A; Wittrock J; Schweizer P
    Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
    Sepp-Lorenzino L; Rosen N
    J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
    Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
    Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
    FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts.
    Ahn JH; Ahn SK; Lee M
    Biochem Biophys Res Commun; 2012 Jan; 417(2):857-63. PubMed ID: 22206679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.
    Buser CA; Dinsmore CJ; Fernandes C; Greenberg I; Hamilton K; Mosser SD; Walsh ES; Williams TM; Koblan KS
    Anal Biochem; 2001 Mar; 290(1):126-37. PubMed ID: 11180946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion.
    Shack S; Chen LC; Miller AC; Danesi R; Samid D
    Int J Cancer; 1995 Sep; 63(1):124-9. PubMed ID: 7558439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
    Kuo ML; Chou YW; Chau YP; Huang TS
    Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
    Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.
    Wesierska-Gadek J; Kramer MP; Schmid G
    J Cell Biochem; 2008 May; 104(1):189-201. PubMed ID: 18022825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.